Mumbai: Aurobindo Pharma has launched its latest drug, Cefpirome, a fourth-generation broad-spectrum injectable Cephalosporin, for the first time in India.
Cefpirome offers enormous advantages in the spectrum of anti-bacterial treatment, especially in life-threatening infections. It is the first in line of the latest in the Cephalosporins group and brings in enormous advantages in the spectrum of coverage of various bacteria that cause disease.
Aurobindo Pharma is all set to launch its own brand of Cefpirome under the brand IV-CEF that will be available in three parenteral dosage forms of 500 mg, 1 gram and 2 grams and will be packed as vials.
Aurobindo's launch of Cefpirome is a particular milestone in resolving complex chemistry, as the drug is the very first in the line of fourth generation treatment and is produced by just two other players in the world.
Cephalosporins are one of the 11 segments in which Aurobindo operates in. Continuous success in launching several first-, second-, third- and fourth-generation sterile as well as oral Cephalosporins has enabled Aurobindo to become one of the world's largest players in this segment.
Aurobindo proposes to launch several Cephalosporins like Cefdinir, Cefprozil and Cefipime, in the near future.